Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jul 1;13:22.
doi: 10.1186/1471-2482-13-22.

Prothrombin Complex Concentrate in the Reduction of Blood Loss During Orthotopic Liver Transplantation: PROTON-trial

Affiliations
Free PMC article
Randomized Controlled Trial

Prothrombin Complex Concentrate in the Reduction of Blood Loss During Orthotopic Liver Transplantation: PROTON-trial

Freeha Arshad et al. BMC Surg. .
Free PMC article

Abstract

Background: In patients with cirrhosis, the synthesis of coagulation factors can fall short, reflected by a prolonged prothrombin time. Although anticoagulants factors are decreased as well, blood loss during orthotopic liver transplantation can still be excessive. Blood loss during orthotopic liver transplantation is currently managed by transfusion of red blood cell concentrates, platelet concentrates, fresh frozen plasma, and fibrinogen concentrate. Transfusion of these products may paradoxically result in an increased bleeding tendency due to aggravated portal hypertension. The hemostatic effect of these products may therefore be overshadowed by bleeding complications due to volume overload.In contrast to these transfusion products, prothrombin complex concentrate is a low-volume highly purified concentrate, containing the four vitamin K dependent coagulation factors. Previous studies have suggested that administration of prothrombin complex concentrate is an effective method to normalize a prolonged prothrombin time in patients with liver cirrhosis. We aim to investigate whether the pre-operative administration of prothrombin complex concentrate in patients undergoing liver transplantation for end-stage liver cirrhosis, is a safe and effective method to reduce perioperative blood loss and transfusion requirements.

Methods/design: This is a double blind, multicenter, placebo-controlled randomized trial.Cirrhotic patients with a prolonged INR (≥1.5) undergoing liver transplantation will be randomized between placebo or prothrombin complex concentrate administration prior to surgery. Demographic, surgical and transfusion data will be recorded. The primary outcome of this study is RBC transfusion requirements.

Discussion: Patients with advanced cirrhosis have reduced plasma levels of both pro- and anticoagulant coagulation proteins. Prothrombin complex concentrate is a low-volume plasma product that contains both procoagulant and anticoagulant proteins and transfusion will not affect the volume status prior to the surgical procedure. We hypothesize that administration of prothrombin complex concentrate will result in a reduction of perioperative blood loss and transfusion requirements. Theoretically, the administration of prothrombin complex concentrate may be associated with a higher risk of thromboembolic complications. Therefore, thromboembolic complications are an important secondary endpoint and the occurrence of this type of complication will be closely monitored during the study.

Trial registration: The trial is registered at http://www.trialregister.nl with number NTR3174. This registry is accepted by the ICMJE.

Similar articles

See all similar articles

Cited by 10 articles

See all "Cited by" articles

References

    1. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116(6):878–885. doi: 10.1182/blood-2010-02-261891. - DOI - PubMed
    1. Peck Radosavljevic M, Wichlas M, Zacherl J, Stiegler G, Stohlawetz P, Fuchsjger M. et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood. 2000;95(3):795–801. - PubMed
    1. Lisman T, Caldwell SH, Leebeek FW, Porte RJ. Is chronic liver disease associated with a bleeding diathesis? J Thromb Haemost. 2006;4(9):2059–2060. doi: 10.1111/j.1538-7836.2006.02075.x. - DOI - PubMed
    1. Witters P, Freson K, Verslype C, Peerlinck K, Hoylaerts M, Nevens F. et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther. 2008;27(11):1017–1029. doi: 10.1111/j.1365-2036.2008.03674.x. - DOI - PubMed
    1. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de-Maat MP, de-Groot PG. et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44(1):53–61. doi: 10.1002/hep.21231. - DOI - PubMed

Publication types

Substances

Feedback